Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis

These authors contributed equally: Mike Wenzel, Luigi Nocera

留言 (0)

沒有登入
gif